Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients

British Journal of Cancer volume 83, pages 719–724 (2000)Cite this article

This article has been updated

Abstract

The prevalence of disease-related BRCA1 mutations was investigated in 642 Dutch breast cancer patients not selected for family history or age at diagnosis. They were tested for germline mutations in the BRCA1 gene using an assay which detects small deletions and insertions (DSDI), as well as the two major genomic founder deletions present in the Dutch population. Data on family history and bilateral breast cancer were obtained retrospectively. Ten protein truncating mutations were detected and one in-frame deletion with an unknown relation to disease risk. Four patients carried the Dutch founder deletion of exon 22. Based on these results the estimated prevalence of breast cancer in the general population in the Netherlands attributable to BRCA1 mutations is 2.1%. Under 40 years-of-age and under 50 years-of-age this prevalence is 9.5% and 6.4%, respectively. All mutation carriers were under 50 years-of-age at diagnosis of the first breast cancer, and five did not have any relative with breast cancer. The proportions of bilateral breast cancer in the mutation carriers and non-carriers did not differ from each other. These data indicate that in the general Dutch breast cancer population the great majority of BRCA1 mutations will be found in women diagnosed under 50 years-of-age. © 2000 Cancer Research Campaign

Download PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N and Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505–514

    CAS  PubMed  PubMed Central  Google Scholar 

  • Coebergh JW, van der Heijden LH and Janssen-Heijnen ML (1995) Cancer incidence and survival. Comprehensive Cancer Center South, 54–55

  • Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T and Weber BL (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409–1415

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Devilee P (1999) BRCA1 and BRCA2 testing: Weighting the demand against the benefits. Am J Hum Genet 64: 943–948

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Easton DF, Ford D and Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265–271

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O’Neil E, Unsal H, Silva AS, Finkelstein DM, Beer RP, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH and Haber DA (1996) Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334: 143–149

    CAS  Article  PubMed  Google Scholar 

  • Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST and Eng CM (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63: 45–51

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Ford D, Easton DF and Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457–1462

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hartge P, Struewing J, Wacholder S, Brody LC and Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64: 963–970

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Hogervorst F, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R and Bakker B (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10: 208–212

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Langston AA, Malone KE, Thompson JD, Daling JR and Ostrander EA (1996) BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334: 137–142

    CAS  Article  Google Scholar 

  • Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van-der-Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG and van’t- Veer LJ (1999) Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer 79: 1475–1478

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Malone KE, Daling JR, Thompson JD, O’Brien CA, Francisco LV and Ostrander EA (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279: 922–929

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Martin JG and Altman GA (1989). Statistics with confidence – confidence intervals and statistical guidelines. British Medical Journal Publications: London

    Google Scholar 

  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barret JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71

    CAS  Article  Google Scholar 

  • Millar SA, Dykes DD and Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215

    Article  Google Scholar 

  • Newman B, Mu H, Butler LM, Millikan RC, Moorman PG and King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279: 915–921

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van-den-Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van-der-Luijt R, van-der-Hout AH, Gille JJ, Pals G, Jedema I, Olmer R, van LI, Newman B, Plandsoen M, van-der-Est M, Brink G, Hageman S, Arts PJ, Bakker MM and Devilee P (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60: 1041–1049

    CAS  PubMed  PubMed Central  Google Scholar 

  • Petrij-Bosch A, Peelen T, van-Vliet M, van-Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers HH, Klijn JG, Vasen HF, Cornelisse CJ, van’t-Veer LJ, Bakker E, van-Ommen GJ and Devilee P (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341–345

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon AL, Steele L, Offit K and Thomas A (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278: 1242–1250

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Shuber AP, Grondin VJ and Klinger KW (1995) A simplified procedure for developing multiplex PCRs. Genome Res 5: 488–493

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Southey MC, Tesoriero A, Andersen CR, Jennings KM, Brown SM, Dite G, Jenkins MA, Osborne RH, Maskiell JA, Porter L, Giles GG, McCredie MR, Hopper JL and Venter DJ (1999) BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer 79: 34–39

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC and Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401–1408

    CAS  Article  Google Scholar 

  • Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner CJ, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA and Garber JE (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2: 1179–1183

    CAS  Article  Google Scholar 

  • Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medical Decision Making, Leiden University Medical Center, The Netherlands

    H Papelard, G H de Bock & T P M Vliet Vlieland

  2. Department of Surgery, Leiden University Medical Center, The Netherlands

    H Papelard & R A E M Tollenaar

  3. Department of Pathology, Leiden University Medical Center, The Netherlands

    R van Eijk, C J Cornelisse & P Devilee

  4. Department of Human and Clinical Genetics, Leiden University Medical Center, The Netherlands

    P Devilee

Authors
  1. H Papelard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G H de Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R van Eijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T P M Vliet Vlieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C J Cornelisse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Devilee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R A E M Tollenaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Papelard, H., de Bock, G., van Eijk, R. et al. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 83, 719–724 (2000). https://doi.org/10.1054/bjoc.2000.1331

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1054/bjoc.2000.1331

Keywords

  • BRCA1 prevalence
  • general breast cancer population
  • Dutch founder mutations

Further reading

Search

Advanced search

Quick links